Algert Global LLC Apellis Pharmaceuticals, Inc. Transaction History

Algert Global LLC

  • $4.77 Billion
  • Q2 2025

A detailed history of Algert Global LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Algert Global LLC holds 154,113 shares of APLS stock, worth $4.17 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
154,113
Previous 338,613 54.49%
Holding current value
$4.17 Million
Previous $7.41 Million 63.97%
% of portfolio
0.06%
Previous 0.18%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 13, 2025
SELL
$16.36 - $23.0 $3.02 Million - $4.24 Million
-184,500 Reduced 54.49%
154,113 $2.67 Million
Q1 2025

May 13, 2025
BUY
$21.87 - $34.63 $1.23 Million - $1.95 Million
56,328 Added 19.95%
338,613 $7.41 Million
Q4 2024

Feb 14, 2025
BUY
$26.18 - $35.42 $5.23 Million - $7.08 Million
199,874 Added 242.53%
282,285 $9.01 Million
Q3 2024

Nov 12, 2024
SELL
$28.84 - $41.15 $1.19 Million - $1.7 Million
-41,217 Reduced 33.34%
82,411 $2.38 Million
Q2 2024

Aug 14, 2024
BUY
$38.07 - $59.71 $2.73 Million - $4.28 Million
71,650 Added 137.85%
123,628 $4.74 Million
Q1 2024

May 14, 2024
BUY
$55.39 - $72.47 $612,004 - $800,721
11,049 Added 27.0%
51,978 $3.06 Million
Q4 2023

Feb 14, 2024
SELL
$37.14 - $64.82 $719,587 - $1.26 Million
-19,375 Reduced 32.13%
40,929 $2.45 Million
Q3 2023

Nov 13, 2023
BUY
$23.65 - $89.22 $768,743 - $2.9 Million
32,505 Added 116.93%
60,304 $2.29 Million
Q2 2023

Aug 14, 2023
SELL
$76.68 - $93.31 $1.14 Million - $1.39 Million
-14,900 Reduced 34.9%
27,799 $2.53 Million
Q1 2023

May 12, 2023
BUY
$46.59 - $66.96 $441,114 - $633,977
9,468 Added 28.49%
42,699 $2.82 Million
Q3 2022

Nov 15, 2022
BUY
$44.76 - $69.66 $82,671 - $128,662
1,847 Added 5.89%
33,231 $2.27 Million
Q2 2022

Aug 15, 2022
BUY
$35.07 - $59.21 $390,013 - $658,474
11,121 Added 54.88%
31,384 $1.42 Million
Q1 2022

May 16, 2022
BUY
$35.46 - $54.12 $457,292 - $697,931
12,896 Added 175.05%
20,263 $1.03 Million
Q4 2021

Feb 14, 2022
BUY
$30.74 - $49.16 $226,461 - $362,161
7,367 New
7,367 $348,000
Q2 2021

Aug 13, 2021
SELL
$40.9 - $64.9 $367,241 - $582,737
-8,979 Closed
0 $0
Q1 2021

May 14, 2021
SELL
$40.8 - $57.39 $955,699 - $1.34 Million
-23,424 Reduced 72.29%
8,979 $385,000
Q4 2020

Feb 12, 2021
SELL
$30.79 - $57.2 $97,665 - $181,438
-3,172 Reduced 8.92%
32,403 $1.85 Million
Q3 2020

Nov 16, 2020
SELL
$25.89 - $33.65 $325,178 - $422,644
-12,560 Reduced 26.09%
35,575 $1.07 Million
Q2 2020

Aug 12, 2020
SELL
$24.8 - $38.49 $43,400 - $67,357
-1,750 Reduced 3.51%
48,135 $1.57 Million
Q1 2020

May 13, 2020
BUY
$17.91 - $44.33 $893,440 - $2.21 Million
49,885 New
49,885 $1.34 Million

Others Institutions Holding APLS

# of Institutions
301
Shares Held
133M
Call Options Held
2.97M
Put Options Held
623K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.97B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email